Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA

Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs),...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of controlled release 2022-10, Vol.350, p.228-243
Hauptverfasser: Arruda, Danielle Campiol, Lachagès, Anne-Marie, Demory, Hélène, Escriou, Guillaume, Lai-Kuen, René, Dugas, Pierre-Yves, Hoffmann, Céline, Bessoles, Stéphanie, Sarrabayrouse, Guillaume, Malachias, Angelo, Finet, Stéphanie, Gastelois, Pedro Lana, de Almeida Macedo, Waldemar Augusto, da Silva Cunha, Armando, Bigey, Pascal, Escriou, Virginie
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 243
container_issue
container_start_page 228
container_title Journal of controlled release
container_volume 350
creator Arruda, Danielle Campiol
Lachagès, Anne-Marie
Demory, Hélène
Escriou, Guillaume
Lai-Kuen, René
Dugas, Pierre-Yves
Hoffmann, Céline
Bessoles, Stéphanie
Sarrabayrouse, Guillaume
Malachias, Angelo
Finet, Stéphanie
Gastelois, Pedro Lana
de Almeida Macedo, Waldemar Augusto
da Silva Cunha, Armando
Bigey, Pascal
Escriou, Virginie
description Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs), and poly (lactic-co-glycolic acid) (PLGA), using a simple modified nanoprecipitation method. Due to their morphology, we called these hybrid nanoparticles Spheroplexes. We elucidated their structure using several physico-chemical techniques and showed that they are composed of a hydrophobic PLGA matrix, surrounded by a lipid envelope adopting a lamellar structure, in which the siRNA is complexed, and they retain surface characteristics identical to the starting nanoparticles, i.e. lipoplexes siRNA. We analyzed the composition of the particle population and determined the final percentage of spheroplexes within this population, 80 to 85% depending on the preparation conditions, using fluorescent markers and the ability of flow cytometry to detect nanometric particles (approximately 200 nm). Finally, we showed that spheroplexes are very stable particles and more efficient than siRNA lipoplexes for the delivery of siRNA to cultured cells. We administered spheroplexes contain siRNAs targeting TNF-α to mice with ulcerative colitis induced by dextran sulfate and our results indicate a disease regression effect with a response probably mediated by their uptake by macrophages / monocytes at the level of lamina propria of the colon. The efficacy of decreased level of TNF-α in vivo seemed to be an association of spheroplexes polymer-lipid composition and the specific siRNA. These results demonstrate that spheroplexes are a promising hybrid nanoparticle for the oral delivery of siRNA to the colon. [Display omitted] •Spheroplexes (Sphx) were developed by a modified nanoprecipitation method using siRNA lipoplexes as starting nanoparticles.•Sphx were spherical nanoparticles with surface characteristics similar to those of lipoplexes.•Sphx were very stable particles and more efficient than siRNA lipoplexes for the in vitro delivery of siRNA.•Sphx were uptake by macrophages/monocytes at the colon with nearly no toxicity after oral administration.•The oral delivery of TNF-α siRNAs Sphx to mice with ulcerative colitis reduced the level of TNF-α and signs of lesions.
doi_str_mv 10.1016/j.jconrel.2022.08.030
format Article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03764331v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365922005351</els_id><sourcerecordid>2705750015</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-d662db3e54a3d45b393acea82cf730568a864176df8041ca146d607efb3c018d3</originalsourceid><addsrcrecordid>eNqFkd1rFDEUxYModlv9E4Q8KnTGm8nn-CJLsV1hUfHjOWSTOzRLOhmT6eL-986yxVefLhx-5xwuh5A3DFoGTL3ft3ufx4Kp7aDrWjAtcHhGVsxo3oi-l8_JauFMw5XsL8hlrXsAkFzol-SCywXoer0i9sd0jyVPCf9g_UA3x12JgX7b3q0b7-aYx-hpitOijW7Mkytz9AnrNR1yoXGkhziXTN0YaC4u0YApHrAcaR5ojd-_rF-RF4NLFV8_3Svy6_bTz5tNs_169_lmvW286PjcBKW6sOMoheNByB3vufPoTOcHzUEq44wSTKswGBDMOyZUUKBx2HEPzAR-Rd6dc-9dslOJD64cbXbRbtZbe9KAayU4Zwe2sG_P7FTy70ess32I1WNKbsT8WG2nQWoJwOSCyjPqS6614PAvm4E97WD39mkHe9rBglmaYPF9PPtw-fkQsdjqI44eQyzoZxty_E_CX6idkPI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2705750015</pqid></control><display><type>article</type><title>Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Arruda, Danielle Campiol ; Lachagès, Anne-Marie ; Demory, Hélène ; Escriou, Guillaume ; Lai-Kuen, René ; Dugas, Pierre-Yves ; Hoffmann, Céline ; Bessoles, Stéphanie ; Sarrabayrouse, Guillaume ; Malachias, Angelo ; Finet, Stéphanie ; Gastelois, Pedro Lana ; de Almeida Macedo, Waldemar Augusto ; da Silva Cunha, Armando ; Bigey, Pascal ; Escriou, Virginie</creator><creatorcontrib>Arruda, Danielle Campiol ; Lachagès, Anne-Marie ; Demory, Hélène ; Escriou, Guillaume ; Lai-Kuen, René ; Dugas, Pierre-Yves ; Hoffmann, Céline ; Bessoles, Stéphanie ; Sarrabayrouse, Guillaume ; Malachias, Angelo ; Finet, Stéphanie ; Gastelois, Pedro Lana ; de Almeida Macedo, Waldemar Augusto ; da Silva Cunha, Armando ; Bigey, Pascal ; Escriou, Virginie</creatorcontrib><description>Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs), and poly (lactic-co-glycolic acid) (PLGA), using a simple modified nanoprecipitation method. Due to their morphology, we called these hybrid nanoparticles Spheroplexes. We elucidated their structure using several physico-chemical techniques and showed that they are composed of a hydrophobic PLGA matrix, surrounded by a lipid envelope adopting a lamellar structure, in which the siRNA is complexed, and they retain surface characteristics identical to the starting nanoparticles, i.e. lipoplexes siRNA. We analyzed the composition of the particle population and determined the final percentage of spheroplexes within this population, 80 to 85% depending on the preparation conditions, using fluorescent markers and the ability of flow cytometry to detect nanometric particles (approximately 200 nm). Finally, we showed that spheroplexes are very stable particles and more efficient than siRNA lipoplexes for the delivery of siRNA to cultured cells. We administered spheroplexes contain siRNAs targeting TNF-α to mice with ulcerative colitis induced by dextran sulfate and our results indicate a disease regression effect with a response probably mediated by their uptake by macrophages / monocytes at the level of lamina propria of the colon. The efficacy of decreased level of TNF-α in vivo seemed to be an association of spheroplexes polymer-lipid composition and the specific siRNA. These results demonstrate that spheroplexes are a promising hybrid nanoparticle for the oral delivery of siRNA to the colon. [Display omitted] •Spheroplexes (Sphx) were developed by a modified nanoprecipitation method using siRNA lipoplexes as starting nanoparticles.•Sphx were spherical nanoparticles with surface characteristics similar to those of lipoplexes.•Sphx were very stable particles and more efficient than siRNA lipoplexes for the in vitro delivery of siRNA.•Sphx were uptake by macrophages/monocytes at the colon with nearly no toxicity after oral administration.•The oral delivery of TNF-α siRNAs Sphx to mice with ulcerative colitis reduced the level of TNF-α and signs of lesions.</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2022.08.030</identifier><identifier>PMID: 35995297</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Biodegradable polymer ; Chemical Sciences ; Delivery system ; Galenic pharmacology ; Hybrid nanoparticle ; Life Sciences ; Lipoplexes ; Medicinal Chemistry ; Oral delivery ; Pharmaceutical sciences ; Polymers ; RNA interference</subject><ispartof>Journal of controlled release, 2022-10, Vol.350, p.228-243</ispartof><rights>2022 Elsevier B.V.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-d662db3e54a3d45b393acea82cf730568a864176df8041ca146d607efb3c018d3</citedby><cites>FETCH-LOGICAL-c423t-d662db3e54a3d45b393acea82cf730568a864176df8041ca146d607efb3c018d3</cites><orcidid>0000-0001-5686-9301 ; 0000-0001-9838-728X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2022.08.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://cnrs.hal.science/hal-03764331$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Arruda, Danielle Campiol</creatorcontrib><creatorcontrib>Lachagès, Anne-Marie</creatorcontrib><creatorcontrib>Demory, Hélène</creatorcontrib><creatorcontrib>Escriou, Guillaume</creatorcontrib><creatorcontrib>Lai-Kuen, René</creatorcontrib><creatorcontrib>Dugas, Pierre-Yves</creatorcontrib><creatorcontrib>Hoffmann, Céline</creatorcontrib><creatorcontrib>Bessoles, Stéphanie</creatorcontrib><creatorcontrib>Sarrabayrouse, Guillaume</creatorcontrib><creatorcontrib>Malachias, Angelo</creatorcontrib><creatorcontrib>Finet, Stéphanie</creatorcontrib><creatorcontrib>Gastelois, Pedro Lana</creatorcontrib><creatorcontrib>de Almeida Macedo, Waldemar Augusto</creatorcontrib><creatorcontrib>da Silva Cunha, Armando</creatorcontrib><creatorcontrib>Bigey, Pascal</creatorcontrib><creatorcontrib>Escriou, Virginie</creatorcontrib><title>Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA</title><title>Journal of controlled release</title><description>Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs), and poly (lactic-co-glycolic acid) (PLGA), using a simple modified nanoprecipitation method. Due to their morphology, we called these hybrid nanoparticles Spheroplexes. We elucidated their structure using several physico-chemical techniques and showed that they are composed of a hydrophobic PLGA matrix, surrounded by a lipid envelope adopting a lamellar structure, in which the siRNA is complexed, and they retain surface characteristics identical to the starting nanoparticles, i.e. lipoplexes siRNA. We analyzed the composition of the particle population and determined the final percentage of spheroplexes within this population, 80 to 85% depending on the preparation conditions, using fluorescent markers and the ability of flow cytometry to detect nanometric particles (approximately 200 nm). Finally, we showed that spheroplexes are very stable particles and more efficient than siRNA lipoplexes for the delivery of siRNA to cultured cells. We administered spheroplexes contain siRNAs targeting TNF-α to mice with ulcerative colitis induced by dextran sulfate and our results indicate a disease regression effect with a response probably mediated by their uptake by macrophages / monocytes at the level of lamina propria of the colon. The efficacy of decreased level of TNF-α in vivo seemed to be an association of spheroplexes polymer-lipid composition and the specific siRNA. These results demonstrate that spheroplexes are a promising hybrid nanoparticle for the oral delivery of siRNA to the colon. [Display omitted] •Spheroplexes (Sphx) were developed by a modified nanoprecipitation method using siRNA lipoplexes as starting nanoparticles.•Sphx were spherical nanoparticles with surface characteristics similar to those of lipoplexes.•Sphx were very stable particles and more efficient than siRNA lipoplexes for the in vitro delivery of siRNA.•Sphx were uptake by macrophages/monocytes at the colon with nearly no toxicity after oral administration.•The oral delivery of TNF-α siRNAs Sphx to mice with ulcerative colitis reduced the level of TNF-α and signs of lesions.</description><subject>Biodegradable polymer</subject><subject>Chemical Sciences</subject><subject>Delivery system</subject><subject>Galenic pharmacology</subject><subject>Hybrid nanoparticle</subject><subject>Life Sciences</subject><subject>Lipoplexes</subject><subject>Medicinal Chemistry</subject><subject>Oral delivery</subject><subject>Pharmaceutical sciences</subject><subject>Polymers</subject><subject>RNA interference</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFkd1rFDEUxYModlv9E4Q8KnTGm8nn-CJLsV1hUfHjOWSTOzRLOhmT6eL-986yxVefLhx-5xwuh5A3DFoGTL3ft3ufx4Kp7aDrWjAtcHhGVsxo3oi-l8_JauFMw5XsL8hlrXsAkFzol-SCywXoer0i9sd0jyVPCf9g_UA3x12JgX7b3q0b7-aYx-hpitOijW7Mkytz9AnrNR1yoXGkhziXTN0YaC4u0YApHrAcaR5ojd-_rF-RF4NLFV8_3Svy6_bTz5tNs_169_lmvW286PjcBKW6sOMoheNByB3vufPoTOcHzUEq44wSTKswGBDMOyZUUKBx2HEPzAR-Rd6dc-9dslOJD64cbXbRbtZbe9KAayU4Zwe2sG_P7FTy70ess32I1WNKbsT8WG2nQWoJwOSCyjPqS6614PAvm4E97WD39mkHe9rBglmaYPF9PPtw-fkQsdjqI44eQyzoZxty_E_CX6idkPI</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Arruda, Danielle Campiol</creator><creator>Lachagès, Anne-Marie</creator><creator>Demory, Hélène</creator><creator>Escriou, Guillaume</creator><creator>Lai-Kuen, René</creator><creator>Dugas, Pierre-Yves</creator><creator>Hoffmann, Céline</creator><creator>Bessoles, Stéphanie</creator><creator>Sarrabayrouse, Guillaume</creator><creator>Malachias, Angelo</creator><creator>Finet, Stéphanie</creator><creator>Gastelois, Pedro Lana</creator><creator>de Almeida Macedo, Waldemar Augusto</creator><creator>da Silva Cunha, Armando</creator><creator>Bigey, Pascal</creator><creator>Escriou, Virginie</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0001-5686-9301</orcidid><orcidid>https://orcid.org/0000-0001-9838-728X</orcidid></search><sort><creationdate>202210</creationdate><title>Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA</title><author>Arruda, Danielle Campiol ; Lachagès, Anne-Marie ; Demory, Hélène ; Escriou, Guillaume ; Lai-Kuen, René ; Dugas, Pierre-Yves ; Hoffmann, Céline ; Bessoles, Stéphanie ; Sarrabayrouse, Guillaume ; Malachias, Angelo ; Finet, Stéphanie ; Gastelois, Pedro Lana ; de Almeida Macedo, Waldemar Augusto ; da Silva Cunha, Armando ; Bigey, Pascal ; Escriou, Virginie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-d662db3e54a3d45b393acea82cf730568a864176df8041ca146d607efb3c018d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biodegradable polymer</topic><topic>Chemical Sciences</topic><topic>Delivery system</topic><topic>Galenic pharmacology</topic><topic>Hybrid nanoparticle</topic><topic>Life Sciences</topic><topic>Lipoplexes</topic><topic>Medicinal Chemistry</topic><topic>Oral delivery</topic><topic>Pharmaceutical sciences</topic><topic>Polymers</topic><topic>RNA interference</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arruda, Danielle Campiol</creatorcontrib><creatorcontrib>Lachagès, Anne-Marie</creatorcontrib><creatorcontrib>Demory, Hélène</creatorcontrib><creatorcontrib>Escriou, Guillaume</creatorcontrib><creatorcontrib>Lai-Kuen, René</creatorcontrib><creatorcontrib>Dugas, Pierre-Yves</creatorcontrib><creatorcontrib>Hoffmann, Céline</creatorcontrib><creatorcontrib>Bessoles, Stéphanie</creatorcontrib><creatorcontrib>Sarrabayrouse, Guillaume</creatorcontrib><creatorcontrib>Malachias, Angelo</creatorcontrib><creatorcontrib>Finet, Stéphanie</creatorcontrib><creatorcontrib>Gastelois, Pedro Lana</creatorcontrib><creatorcontrib>de Almeida Macedo, Waldemar Augusto</creatorcontrib><creatorcontrib>da Silva Cunha, Armando</creatorcontrib><creatorcontrib>Bigey, Pascal</creatorcontrib><creatorcontrib>Escriou, Virginie</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arruda, Danielle Campiol</au><au>Lachagès, Anne-Marie</au><au>Demory, Hélène</au><au>Escriou, Guillaume</au><au>Lai-Kuen, René</au><au>Dugas, Pierre-Yves</au><au>Hoffmann, Céline</au><au>Bessoles, Stéphanie</au><au>Sarrabayrouse, Guillaume</au><au>Malachias, Angelo</au><au>Finet, Stéphanie</au><au>Gastelois, Pedro Lana</au><au>de Almeida Macedo, Waldemar Augusto</au><au>da Silva Cunha, Armando</au><au>Bigey, Pascal</au><au>Escriou, Virginie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA</atitle><jtitle>Journal of controlled release</jtitle><date>2022-10</date><risdate>2022</risdate><volume>350</volume><spage>228</spage><epage>243</epage><pages>228-243</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>Vectorized small interfering RNAs (siRNAs) are widely used to induce gene silencing. Among the delivery systems used, lipid-based particles are the most effective. Our objective was the development of novel lipid-polymer hybrid nanoparticles, from lipoplexes (complexes of cationic lipid and siRNAs), and poly (lactic-co-glycolic acid) (PLGA), using a simple modified nanoprecipitation method. Due to their morphology, we called these hybrid nanoparticles Spheroplexes. We elucidated their structure using several physico-chemical techniques and showed that they are composed of a hydrophobic PLGA matrix, surrounded by a lipid envelope adopting a lamellar structure, in which the siRNA is complexed, and they retain surface characteristics identical to the starting nanoparticles, i.e. lipoplexes siRNA. We analyzed the composition of the particle population and determined the final percentage of spheroplexes within this population, 80 to 85% depending on the preparation conditions, using fluorescent markers and the ability of flow cytometry to detect nanometric particles (approximately 200 nm). Finally, we showed that spheroplexes are very stable particles and more efficient than siRNA lipoplexes for the delivery of siRNA to cultured cells. We administered spheroplexes contain siRNAs targeting TNF-α to mice with ulcerative colitis induced by dextran sulfate and our results indicate a disease regression effect with a response probably mediated by their uptake by macrophages / monocytes at the level of lamina propria of the colon. The efficacy of decreased level of TNF-α in vivo seemed to be an association of spheroplexes polymer-lipid composition and the specific siRNA. These results demonstrate that spheroplexes are a promising hybrid nanoparticle for the oral delivery of siRNA to the colon. [Display omitted] •Spheroplexes (Sphx) were developed by a modified nanoprecipitation method using siRNA lipoplexes as starting nanoparticles.•Sphx were spherical nanoparticles with surface characteristics similar to those of lipoplexes.•Sphx were very stable particles and more efficient than siRNA lipoplexes for the in vitro delivery of siRNA.•Sphx were uptake by macrophages/monocytes at the colon with nearly no toxicity after oral administration.•The oral delivery of TNF-α siRNAs Sphx to mice with ulcerative colitis reduced the level of TNF-α and signs of lesions.</abstract><pub>Elsevier B.V</pub><pmid>35995297</pmid><doi>10.1016/j.jconrel.2022.08.030</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-5686-9301</orcidid><orcidid>https://orcid.org/0000-0001-9838-728X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0168-3659
ispartof Journal of controlled release, 2022-10, Vol.350, p.228-243
issn 0168-3659
1873-4995
language eng
recordid cdi_hal_primary_oai_HAL_hal_03764331v1
source ScienceDirect Journals (5 years ago - present)
subjects Biodegradable polymer
Chemical Sciences
Delivery system
Galenic pharmacology
Hybrid nanoparticle
Life Sciences
Lipoplexes
Medicinal Chemistry
Oral delivery
Pharmaceutical sciences
Polymers
RNA interference
title Spheroplexes: Hybrid PLGA-cationic lipid nanoparticles, for in vitro and oral delivery of siRNA
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A12%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spheroplexes:%20Hybrid%20PLGA-cationic%20lipid%20nanoparticles,%20for%20in%20vitro%20and%20oral%20delivery%20of%20siRNA&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Arruda,%20Danielle%20Campiol&rft.date=2022-10&rft.volume=350&rft.spage=228&rft.epage=243&rft.pages=228-243&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2022.08.030&rft_dat=%3Cproquest_hal_p%3E2705750015%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2705750015&rft_id=info:pmid/35995297&rft_els_id=S0168365922005351&rfr_iscdi=true